Journal Article
. 2010 Mar;28(11).
doi: 10.1200/JCO.2009.24.4798.

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

Mitch Dowsett 1 Jack Cuzick  Christopher Wale  John Forbes  Elizabeth A Mallon  Janine Salter  Emma Quinn  Anita Dunbier  Michael Baum  Aman Buzdar  Anthony Howell  Roberto Bugarini  Frederick L Baehner  Steven Shak  
Affiliations
  • PMID: 20212256
  •     227 citations

Abstract

PURPOSE To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the tamoxifen and anastrozole arms of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial. PATIENTS AND METHODS RNA was extracted from 1,372 tumor blocks from postmenopausal patients with hormone receptor-positive primary breast cancer in the monotherapy arms of ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, and the RS was calculated. Cox proportional hazards models assessed the value of adding RS to a model with clinical variables (age, tumor size, grade, and treatment) in node-negative (N0) and node-positive (N+) women. RESULTS Reportable scores were available from 1,231 evaluable patients (N0, n = 872; N+, n = 306; and node status unknown, n = 53); 72, 74, and six DRs occurred in N0, N+, and node status unknown patients, respectively. For both N0 and N+ patients, RS was significantly associated with time to DR in multivariate analyses (P < .001 for N0 and P = .002 for N+). RS also showed significant prognostic value beyond that provided by Adjuvant! Online (P < .001). Nine-year DR rates in low (RS < 18), intermediate (RS = 18 to 30), and high RS (RS > or = 31) groups were 4%, 12%, and 25%, respectively, in N0 patients and 17%, 28%, and 49%, respectively, in N+ patients. The prognostic value of RS was similar in anastrozole- and tamoxifen-treated patients. CONCLUSION This study confirmed the performance of RS in postmenopausal HR+ patients treated with tamoxifen in a large contemporary population and demonstrated that RS is an independent predictor of DR in N0 and N+ hormone receptor-positive patients treated with anastrozole, adding value to estimates with standard clinicopathologic features.

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.
Ruth Oratz, Benjamin Kim, +4 authors, Michael Broder.
J Oncol Pract, 2011 Jul 07; 7(2). PMID: 21731516    Free PMC article.
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.
Pierre-Emmanuel Colombo, Fernanda Milanezi, Britta Weigelt, Jorge S Reis-Filho.
Breast Cancer Res, 2011 Jul 27; 13(3). PMID: 21787441    Free PMC article.
Review.
Do all patients with breast cancer require systemic adjuvant therapy?
Jennifer J Griggs, Daniel F Hayes.
J Natl Cancer Inst, 2011 Sep 02; 103(18). PMID: 21881041    Free PMC article.
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.
Arif H Kamal, Charles L Loprinzi, +7 authors, Matthew P Goetz.
Oncologist, 2011 Sep 22; 16(10). PMID: 21934103    Free PMC article.
Use of Oncotype DX in Women with Node-Positive Breast Cancer.
Naoko Ishibe, Sheri Schully, Andrew Freedman, Scott David Ramsey.
PLoS Curr, 2011 Oct 11; 3. PMID: 21984342    Free PMC article.
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
Rachel C Jankowitz, Kristine Cooper, +5 authors, Adam Brufsky.
Breast Cancer Res, 2011 Oct 18; 13(5). PMID: 21999244    Free PMC article.
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Gong Tang, Jack Cuzick, +6 authors, Norman Wolmark.
J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010013    Free PMC article.
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.
Muaiad Kittaneh, Stefan Glück.
Breast Cancer (Auckl), 2011 Nov 16; 5. PMID: 22084574    Free PMC article.
Practical implications of gene-expression-based assays for breast oncologists.
Aleix Prat, Matthew J Ellis, Charles M Perou.
Nat Rev Clin Oncol, 2011 Dec 07; 9(1). PMID: 22143140    Free PMC article.
Highly Cited. Review.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.
Isabel Pinhel, Margaret Hills, +10 authors, NCRI Adjuvant Breast Cancer Trial Management Group.
Breast Cancer Res, 2012 Mar 16; 14(2). PMID: 22417870    Free PMC article.
Patients with positive axillary lymph nodes: how to use genomic assays.
Ruta Rao.
Curr Treat Options Oncol, 2012 Mar 20; 13(2). PMID: 22426945
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Katja Lundgren, Matthew Brown, +7 authors, TransATAC investigators.
Breast Cancer Res, 2012 Apr 06; 14(2). PMID: 22475046    Free PMC article.
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
S Barton, L Zabaglo, +6 authors, M Dowsett.
Br J Cancer, 2012 Apr 26; 106(11). PMID: 22531639    Free PMC article.
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.
A Prat, J S Parker, +9 authors, C M Perou.
Ann Oncol, 2012 Apr 26; 23(11). PMID: 22532584    Free PMC article.
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?
Jeffrey G Schneider, Danny N Khalil.
Breast Cancer Res Treat, 2012 Jun 23; 134(3). PMID: 22723033    Free PMC article.
High-risk estrogen-receptor-positive breast cancer: identification and implications for therapy.
Rosemary L Balleine, Nicholas R Wilcken.
Mol Diagn Ther, 2012 Jul 21; 16(4). PMID: 22812573
Review.
Understanding how breast cancer patients use risk information from genomic tests.
Jessica T DeFrank, Lisa A Carey, Noel T Brewer.
J Behav Med, 2012 Aug 11; 36(6). PMID: 22878783    Free PMC article.
Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS.
Nadiyah Sulayman, Elizabeth Spellman, +4 authors, Suzanne C O'Neill.
J Cancer Epidemiol, 2012 Aug 18; 2012. PMID: 22899924    Free PMC article.
Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
Mohamed Elfagieh, Fathi Abdalla, +3 authors, Abdelbaset Buhmeida.
Tumour Biol, 2012 Sep 06; 33(6). PMID: 22948780
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007).
William B Wong, Scott D Ramsey, +2 authors, David L Veenstra.
Contemp Clin Trials, 2012 Sep 18; 33(6). PMID: 22981891    Free PMC article.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
W Eiermann, M Rezai, +13 authors, J Blohmer.
Ann Oncol, 2012 Nov 09; 24(3). PMID: 23136233    Free PMC article.
Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor-positive, one-to-three positive axillary lymph node, breast cancer.
M B Hannouf, M Brackstone, B Xie, G S Zaric.
Curr Oncol, 2012 Nov 13; 19(5). PMID: 23144580    Free PMC article.
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients.
Michael R Mallmann, Andrea Staratschek-Jox, +5 authors, Joachim L Schultze.
EPMA J, 2010 Sep 01; 1(3). PMID: 23199086    Free PMC article.
Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.
Elizabeth Spellman, Nadiyah Sulayman, +4 authors, Suzanne C O'Neill.
Psychooncology, 2013 Mar 01; 22(9). PMID: 23447452    Free PMC article.
A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.
Jie Shen, Jia Wei, +9 authors, Baorui Liu.
J Transl Med, 2013 Mar 23; 11. PMID: 23517622    Free PMC article.
Development and validation of a 32-gene prognostic index for prostate cancer progression.
Chin-Lee Wu, Brock E Schroeder, +8 authors, W Scott McDougal.
Proc Natl Acad Sci U S A, 2013 Mar 28; 110(15). PMID: 23533275    Free PMC article.
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.
Jeffrey B Smerage, G Thomas Budd, +9 authors, Daniel F Hayes.
Mol Oncol, 2013 Mar 30; 7(3). PMID: 23538216    Free PMC article.
Breast cancer genomics: challenges in interpretation and application.
Cathy M Kelly, W Fraser Symmans, Eleni Andreopoulou, Giampaolo Bianchini.
Oncologist, 2013 May 02; 18(4). PMID: 23633449    Free PMC article.
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses.
Roman Rouzier, Paolo Pronzato, +3 authors, William J Valentine.
Breast Cancer Res Treat, 2013 Jun 01; 139(3). PMID: 23722312    Free PMC article.
Systematic Review.
The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
Salomon M Stemmer, Shmuel H Klang, +7 authors, Nicky Lieberman.
Breast Cancer Res Treat, 2013 Jun 27; 140(1). PMID: 23801158    Free PMC article.
Luminal breast cancer: from biology to treatment.
Michail Ignatiadis, Christos Sotiriou.
Nat Rev Clin Oncol, 2013 Jul 25; 10(9). PMID: 23881035
Review.
Who gets genomic testing for breast cancer recurrence risk?
J T DeFrank, T Salz, K Reeder-Hayes, N T Brewer.
Public Health Genomics, 2013 Aug 01; 16(5). PMID: 23899493    Free PMC article.
WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
Daniel Hofmann, Ulrike Nitz, +4 authors, Nadia Harbeck.
Trials, 2013 Aug 21; 14. PMID: 23958221    Free PMC article.
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Ivana Sestak, Mitch Dowsett, +4 authors, Jack Cuzick.
J Natl Cancer Inst, 2013 Sep 14; 105(19). PMID: 24029245    Free PMC article.
Highly Cited.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.
Dejan Knezevic, Audrey D Goddard, +8 authors, Christopher Quale.
BMC Genomics, 2013 Oct 10; 14. PMID: 24103217    Free PMC article.
Highly Cited.
p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Mitsugu Yamamoto, Mitsuchika Hosoda, +6 authors, Hiroko Yamashita.
Cancer Sci, 2013 Oct 15; 105(1). PMID: 24118529    Free PMC article.
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Irene Moy, Zhihong Lin, +3 authors, Serdar E Bulun.
PLoS One, 2013 Nov 14; 8(11). PMID: 24223121    Free PMC article.
Molecular profiling for breast cancer: a comprehensive review.
Muaiad Kittaneh, Alberto J Montero, Stefan Glück.
Biomark Cancer, 2013 Nov 20; 5. PMID: 24250234    Free PMC article.
Review.
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
Suzanne A Eccles, Eric O Aboagye, +84 authors, Alastair M Thompson.
Breast Cancer Res, 2013 Nov 30; 15(5). PMID: 24286369    Free PMC article.
Highly Cited. Review.
Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Malek B Hannouf, Bin Xie, Muriel Brackstone, Gregory S Zaric.
Pharmacoeconomics, 2013 Nov 30; 32(2). PMID: 24288208
The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy.
Nava Siegelmann-Danieli, Barbara Silverman, +3 authors, Avi Porath.
Ecancermedicalscience, 2014 Jan 05; 7. PMID: 24386009    Free PMC article.
Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.
Anna Tessari, Dario Palmieri, Serena Di Cosimo.
Pharmgenomics Pers Med, 2014 Jan 10; 7. PMID: 24403841    Free PMC article.
Review.
Breast Cancer Biomarkers: Utility in Clinical Practice.
Fanny Le Du, Naoto T Ueno, Ana M Gonzalez-Angulo.
Curr Breast Cancer Rep, 2014 Jan 15; 5(4). PMID: 24416469    Free PMC article.
Oncotype dx results in multiple primary breast cancers.
Michael J Toole, Kelley M Kidwell, Catherine Van Poznak.
Breast Cancer (Auckl), 2014 Jan 24; 8. PMID: 24453493    Free PMC article.
Molecular tests as prognostic factors in breast cancer.
Marc J van de Vijver.
Virchows Arch, 2014 Feb 04; 464(3). PMID: 24487789
Review.
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.
Georgeta Fried, Mor Moskovitz.
Springerplus, 2014 Feb 26; 3. PMID: 24567880    Free PMC article.
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow.
Bahriye Aktas, Agnes Bankfalvi, +2 authors, Sabine Kasimir-Bauer.
Mol Clin Oncol, 2014 Mar 22; 1(6). PMID: 24649291    Free PMC article.
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
J Wason, A Marshall, +2 authors, N Stallard.
Br J Cancer, 2014 Mar 29; 110(8). PMID: 24667651    Free PMC article.
Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.
Ahmed Bilal Ashraf, Dania Daye, +4 authors, Despina Kontos.
Radiology, 2014 Apr 08; 272(2). PMID: 24702725    Free PMC article.
Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
Geetika Srivastava, Lindsay A Renfro, +10 authors, Steven R Alberts.
Oncologist, 2014 Apr 09; 19(5). PMID: 24710310    Free PMC article.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Miguel Martin, Jan C Brase, +15 authors, Alvaro Rodriguez-Lescure.
Breast Cancer Res, 2014 Apr 15; 16(2). PMID: 24725534    Free PMC article.
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Adam M Brufsky.
Am J Clin Oncol, 2014 May 24; 37(4). PMID: 24853663    Free PMC article.
Systematic Review.
Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.
Alex Farr, Rachel Wuerstlein, +2 authors, Nadia Harbeck.
Rev Obstet Gynecol, 2013 Jan 01; 6(3-4). PMID: 24920978    Free PMC article.
How does genome sequencing impact surgery?
Marlies S Reimers, Charla C Engels, +2 authors, Gerrit J Liefers.
Nat Rev Clin Oncol, 2014 Jun 25; 11(10). PMID: 24958181
Review.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Review.
Genome-based risk prediction for early stage breast cancer.
Christina Adaniel, Komal Jhaveri, Adriana Heguy, Francisco J Esteva.
Oncologist, 2014 Sep 05; 19(10). PMID: 25187476    Free PMC article.
Review.
Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
Hideko Yamauchi, Chizuko Nakagawa, +9 authors, Seigo Nakamura.
BMC Health Serv Res, 2014 Sep 06; 14. PMID: 25190451    Free PMC article.
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.
Kevin Kalinsky, Emerson A Lim, +10 authors, Dawn L Hershman.
Cancer Invest, 2014 Sep 26; 32(9). PMID: 25254601    Free PMC article.
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.
Elizabeth Miller, Hee Jin Lee, +3 authors, Bora Lim.
F1000Res, 2014 Nov 18; 3. PMID: 25400908    Free PMC article.
Review.
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
Amalia M Issa, Vivek S Chaudhari, Gary E Marchant.
Expert Rev Mol Diagn, 2014 Dec 06; 15(2). PMID: 25479414    Free PMC article.
Review.
Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Maurice P H M Jansen, Leen Sas, +20 authors, Steven Van Laere.
Mol Oncol, 2015 Mar 17; 9(6). PMID: 25771305    Free PMC article.
Ki67--no evidence for its use in node-positive breast cancer.
Fabrice Andre, Monica Arnedos, +2 authors, Suzette Delaloge.
Nat Rev Clin Oncol, 2015 Mar 18; 12(5). PMID: 25781576
Review.
A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer.
Thomas G Frazier, Kevin R Fox, +13 authors, Michael S Broder.
Pharmaceuticals (Basel), 2015 Mar 20; 8(1). PMID: 25789420    Free PMC article.
[Molecular pathology for breast cancer: Importance of the gene expression profile].
C Denkert, B M Pfitzner, B I Heppner, M Dietel.
Pathologe, 2015 Apr 04; 36(2). PMID: 25836324
Review.
Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.
A Eisen, G G Fletcher, +5 authors, members of the Early Breast Cancer Systemic Therapy Consensus Panel.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848340    Free PMC article.
Markers for the identification of late breast cancer recurrence.
Ivana Sestak, Jack Cuzick.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848913    Free PMC article.
Review.
Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.
Elizabeth J Sutton, Jung Hun Oh, +5 authors, Elizabeth A Morris.
J Magn Reson Imaging, 2015 Apr 09; 42(5). PMID: 25850931    Free PMC article.
Highly Cited.
Role of genetic and molecular profiling in sarcomas.
Scott M Norberg, Sujana Movva.
Curr Treat Options Oncol, 2015 May 06; 16(5). PMID: 25939540
Review.
Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.
Gregory P Hess, Eileen Fonseca, Rachel Scott, Jesen Fagerness.
Genet Res (Camb), 2015 Jun 02; 97. PMID: 26030725    Free PMC article.
Review.
Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
Yi-Zi Zheng, Lei Wang, Xin Hu, Zhi-Ming Shao.
Oncotarget, 2015 Jun 04; 6(26). PMID: 26036636    Free PMC article.
Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
Gregory Katz, Olivier Romano, +7 authors, Rémy Salmon.
PLoS One, 2015 Jun 19; 10(6). PMID: 26086912    Free PMC article.
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
Joseph Gligorov, Xavier B Pivot, +11 authors, Francilian Breast Intergroup.
Oncologist, 2015 Jun 27; 20(8). PMID: 26112003    Free PMC article.
Using prior knowledge from cellular pathways and molecular networks for diagnostic specimen classification.
Enrico Glaab.
Brief Bioinform, 2015 Jul 05; 17(3). PMID: 26141830    Free PMC article.
Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.
B Yeo, L Zabaglo, +3 authors, M Dowsett.
Br J Cancer, 2015 Jul 17; 113(3). PMID: 26180920    Free PMC article.
Cancer biomarker discovery and validation.
Nicolas Goossens, Shigeki Nakagawa, Xiaochen Sun, Yujin Hoshida.
Transl Cancer Res, 2015 Jul 28; 4(3). PMID: 26213686    Free PMC article.
Highly Cited.
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.
J Ribeiro, B Sousa, F Cardoso.
EJC Suppl, 2013 Sep 01; 11(2). PMID: 26217109    Free PMC article.
Review.
Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?
Niamh Conlon, Dara S Ross, +3 authors, Lee K Tan.
Breast J, 2015 Aug 15; 21(5). PMID: 26271749    Free PMC article.
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.
Suzanne C O'Neill, Claudine Isaacs, +8 authors, Arnold L Potosky.
J Natl Compr Canc Netw, 2015 Oct 21; 13(10). PMID: 26483061    Free PMC article.
Chemotherapy and the recurrence score--results as expected?
Lajos Pusztai.
Nat Rev Clin Oncol, 2015 Nov 11; 12(12). PMID: 26552957
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Megan C Roberts, Morris Weinberger, +5 authors, Stephanie B Wheeler.
J Clin Oncol, 2015 Nov 26; 34(2). PMID: 26598755    Free PMC article.
Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age.
Sandra M Swain, Raquel Nunes, +2 authors, Amy P Sing.
Adv Ther, 2015 Nov 28; 32(12). PMID: 26610382    Free PMC article.
A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
Michael D Alvarado, Che Prasad, +5 authors, Christos J Markopoulos.
Adv Ther, 2015 Nov 28; 32(12). PMID: 26610383    Free PMC article.
Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression.
Michael R Crager, Gong Tang.
J Appl Stat, 2014 Jan 01; 41(12). PMID: 26664111    Free PMC article.
TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays.
Ching-Hung Lin, I-Chiun Chen, +11 authors, Ann-Lii Cheng.
Sci Rep, 2015 Dec 17; 5. PMID: 26671300    Free PMC article.
Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.
Genet Med, 2015 Dec 19; 18(8). PMID: 26681310
Breast cancer intrinsic subtype classification, clinical use and future trends.
Xiaofeng Dai, Ting Li, +4 authors, Bozhi Shi.
Am J Cancer Res, 2015 Dec 23; 5(10). PMID: 26693050    Free PMC article.
Highly Cited. Review.
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Dennis C Sgroi, Judy-Anne W Chapman, +10 authors, Michael Pollak.
Breast Cancer Res, 2016 Jan 06; 18(1). PMID: 26728744    Free PMC article.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Meagan B Myers.
Pharmgenomics Pers Med, 2016 Feb 10; 9. PMID: 26858530    Free PMC article.
Review.
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Miguel Martin, Jan C Brase, +15 authors, Alvaro Rodriguez-Lescure.
Breast Cancer Res Treat, 2016 Feb 26; 156(1). PMID: 26909792    Free PMC article.
The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Anna Kuchel, Tim Robinson, +8 authors, Jeremy P Braybrooke.
Br J Cancer, 2016 Mar 10; 114(7). PMID: 26954715    Free PMC article.
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
Tari A King, Jaclyn P Lyman, +17 authors, Clifford A Hudis.
J Clin Oncol, 2016 Mar 24; 34(20). PMID: 27001590    Free PMC article.
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
John M S Bartlett, Jane Bayani, +18 authors, OPTIMA TMG.
J Natl Cancer Inst, 2016 May 01; 108(9). PMID: 27130929    Free PMC article.
Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Takashi Eguchi, Kyuichi Kadota, +13 authors, Prasad S Adusumilli.
Oncotarget, 2016 May 07; 7(23). PMID: 27153551    Free PMC article.
Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Su Hyun Lee, Seunggyun Ha, +9 authors, Gi Jeong Cheon.
Eur J Nucl Med Mol Imaging, 2016 May 23; 43(9). PMID: 27209424
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Norman Wolmark, Eleftherios P Mamounas, +6 authors, Soonmyung Paik.
J Clin Oncol, 2016 May 25; 34(20). PMID: 27217450    Free PMC article.
The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
Josee-Lyne Ethier, Eitan Amir.
Mol Diagn Ther, 2016 May 29; 20(4). PMID: 27235162
Review.
Breast cancer multigene testing trends and impact on chemotherapy use.
G Thomas Ray, Jeanne Mandelblatt, +4 authors, Tracy A Lieu.
Am J Manag Care, 2016 Jun 09; 22(5). PMID: 27266581    Free PMC article.
Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely (®) Initiative.
Jeffrey Landercasper, Lisa Bailey, +14 authors, Steven L Chen.
Ann Surg Oncol, 2016 Jun 24; 23(10). PMID: 27334216    Free PMC article.
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Richard Buus, Ivana Sestak, +7 authors, Mitch Dowsett.
J Natl Cancer Inst, 2016 Jul 13; 108(11). PMID: 27400969    Free PMC article.
Highly Cited.
Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.
Ivana Sestak, Mitch Dowsett, +2 authors, Jack Cuzick.
Breast Cancer Res Treat, 2016 Jul 23; 159(1). PMID: 27447876    Free PMC article.
21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
Benjamin M Parsons, Jeffrey Landercasper, +3 authors, Leah L Dietrich.
Breast Cancer Res Treat, 2016 Aug 11; 159(2). PMID: 27507245    Free PMC article.
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Jan C Brase, Ralf Kronenwett, +2 authors, Marcus Schmidt.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605191    Free PMC article.
Review.
Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.
Vida Pourteimoor, Samira Mohammadi-Yeganeh, Mahdi Paryan.
Tumour Biol, 2016 Sep 22; 37(11). PMID: 27651157
Review.
The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Esther J Campbell, Mathias Tesson, +3 authors, Joanne Edwards.
Br J Cancer, 2016 Sep 23; 115(8). PMID: 27657341    Free PMC article.
The analytical validation of the Oncotype DX Recurrence Score assay.
Frederick L Baehner.
Ecancermedicalscience, 2016 Oct 13; 10. PMID: 27729940    Free PMC article.
Estimating the OncotypeDX score: validation of an inexpensive estimation tool.
Anne A Eaton, Catherine E Pesce, +5 authors, Mahmoud El-Tamer.
Breast Cancer Res Treat, 2016 Dec 09; 161(3). PMID: 27928699    Free PMC article.
Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients.
Matthew G Hanna, Ira J Bleiweiss, Anupma Nayak, Shabnam Jaffer.
Int J Breast Cancer, 2017 Feb 09; 2017. PMID: 28168058    Free PMC article.
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Carlos H Barcenas, Akshara Raghavendra, +10 authors, Debu Tripathy.
Cancer, 2017 Feb 16; 123(13). PMID: 28199747    Free PMC article.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Review.
21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.
Julie A Lynch, Brygida Berse, Nicole Coomer, John Kautter.
Genet Med, 2017 Mar 24; 19(10). PMID: 28333918
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.
Gyungyub Gong, Mi Jeong Kwon, +15 authors, Young Kee Shin.
Sci Rep, 2017 Mar 30; 7. PMID: 28350001    Free PMC article.
Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.
Jiayi Wu, Yan Fang, +11 authors, Kunwei Shen.
Oncotarget, 2017 Apr 14; 8(24). PMID: 28404972    Free PMC article.
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Bernhard C Pestalozzi, Christoph Tausch, +17 authors, Swiss Group for Clinical Cancer Research (SAKK).
BMC Cancer, 2017 Apr 15; 17(1). PMID: 28407750    Free PMC article.
Towards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.
Daniel M Trifiletti, Vanessa N Sturz, Timothy N Showalter, Jennifer M Lobo.
PLoS One, 2017 May 10; 12(5). PMID: 28486497    Free PMC article.
Systematic Review.
A high-throughput method to detect RNA profiling by integration of RT-MLPA with next generation sequencing technology.
Jing Wang, Xue Yang, +5 authors, Jidong Gao.
Oncotarget, 2017 May 26; 8(28). PMID: 28545022    Free PMC article.
Clinical utility of gene-expression signatures in early stage breast cancer.
Maryann Kwa, Andreas Makris, Francisco J Esteva.
Nat Rev Clin Oncol, 2017 Jun 01; 14(10). PMID: 28561071
Highly Cited. Review.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.
Terri P McVeigh, Michael J Kerin.
Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971    Free PMC article.
Review.
Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.
Maura Bríd Cotter, Alex Dakin, +5 authors, Cecily M Quinn.
Virchows Arch, 2017 Jul 15; 471(3). PMID: 28707056
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.
Holly Janes, Marshall D Brown, +2 authors, William E Barlow.
Contemp Clin Trials, 2017 Aug 19; 63. PMID: 28818434    Free PMC article.
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +13 authors, Noa Ben-Baruch.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900632    Free PMC article.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +21 authors, Nicky Liebermann.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900633    Free PMC article.
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting.
Laura Pizzuti, Clara Natoli, +13 authors, Patrizia Vici.
Oncotarget, 2017 Oct 06; 8(40). PMID: 28978178    Free PMC article.
Characterisation of the immune-related transcriptome in resected biliary tract cancers.
Michele Ghidini, Luciano Cascione, +17 authors, Chiara Braconi.
Eur J Cancer, 2017 Oct 11; 86. PMID: 28988016    Free PMC article.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer.
E Nilüfer Güler.
Eur J Breast Health, 2017 Oct 31; 13(4). PMID: 29082373    Free PMC article.
Review.
Clinical utility of multigene profiling assays in early-stage breast cancer.
M C Chang, L H Souter, +6 authors, Molecular Oncology Advisory Committee.
Curr Oncol, 2017 Nov 02; 24(5). PMID: 29089811    Free PMC article.
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Andrew Dodson, David Okonji, +6 authors, Mitch Dowsett.
Breast Cancer Res Treat, 2017 Nov 13; 168(1). PMID: 29128896    Free PMC article.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Eleftherios P Mamounas, Gong Tang, +14 authors, Norman Wolmark.
Breast Cancer Res Treat, 2017 Nov 13; 168(1). PMID: 29128898    Free PMC article.
Molecular Subtypes and Local-Regional Control of Breast Cancer.
Simona Maria Fragomeni, Andrew Sciallis, Jacqueline S Jeruss.
Surg Oncol Clin N Am, 2017 Nov 15; 27(1). PMID: 29132568    Free PMC article.
Review.
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Maria Vittoria Dieci, Valentina Guarneri, +15 authors, PierFranco Conte.
Oncologist, 2017 Nov 15; 23(3). PMID: 29133514    Free PMC article.
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.
Ling Xin, Yin-Hua Liu, Tracey A Martin, Wen G Jiang.
World J Oncol, 2017 Nov 18; 8(2). PMID: 29147432    Free PMC article.
Review.
Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.
Nita Amornsiripanitch, Vicky T Nguyen, +4 authors, Savannah C Partridge.
J Magn Reson Imaging, 2017 Nov 28; 48(1). PMID: 29178616    Free PMC article.
Large-scale DNA organization is a prognostic marker of breast cancer survival.
Martial Guillaud, Qian Ye, +5 authors, Mira Keyes.
Med Oncol, 2017 Dec 08; 35(1). PMID: 29214466
Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?
I S Bhattacharya, A M Kirby, J M Bliss, C E Coles.
Clin Oncol (R Coll Radiol), 2018 Jan 15; 30(3). PMID: 29331262    Free PMC article.
Review.
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Sofia Torres, Maureen Trudeau, +7 authors, Andrea Eisen.
Oncologist, 2018 Jan 27; 23(7). PMID: 29371476    Free PMC article.
Luminal A Breast Cancer and Molecular Assays: A Review.
Jennifer J Gao, Sandra M Swain.
Oncologist, 2018 Feb 24; 23(5). PMID: 29472313    Free PMC article.
Review.
Spotlight on the utility of the Oncotype DX® breast cancer assay.
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann.
Int J Womens Health, 2018 Mar 06; 10. PMID: 29503586    Free PMC article.
Review.
Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.
Onur Esbah, Berna Oksuzoglu.
Indian J Med Res, 2018 Mar 08; 146(5). PMID: 29512598    Free PMC article.
Review.
Investigating a multigene prognostic assay based on significant pathways for Luminal A breast cancer through gene expression profile analysis.
Haiyan Gao, Mei Yang, Xiaolan Zhang.
Oncol Lett, 2018 Mar 17; 15(4). PMID: 29545900    Free PMC article.
Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
Shi-Yi Wang, Weixiong Dang, +3 authors, Cary P Gross.
J Clin Oncol, 2018 Apr 17; 36(16). PMID: 29659329    Free PMC article.
Systematic Review.
Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.
S Aggarwal, A Vaid, +10 authors, D Doval.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721472    Free PMC article.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Frédérique Penault-Llorca, Thomas Filleron, +12 authors, Henri Roché.
BMC Cancer, 2018 May 08; 18(1). PMID: 29728098    Free PMC article.
A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score.
Feilin Qu, Xiaosong Chen, +10 authors, Kunwei Shen.
Chin J Cancer Res, 2018 Jun 05; 30(2). PMID: 29861607    Free PMC article.
The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine.
Kivilcim Ozturk, Michelle Dow, +2 authors, Hannah Carter.
J Mol Biol, 2018 Jun 18; 430(18 Pt A). PMID: 29908887    Free PMC article.
Review.
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Danielle M Bello, Christy Russell, +2 authors, Monica Morrow.
Ann Surg Oncol, 2018 Jul 04; 25(10). PMID: 29968028    Free PMC article.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Review.
Genomic Testing in the Management of Early-Stage Breast Cancer.
Sima Ehsani, Kari Braun Wisinski.
J Clin Outcomes Manag, 2017 May 01; 24(5). PMID: 30158821    Free PMC article.
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Richard Buus, Belinda Yeo, +7 authors, Mitch Dowsett.
Breast Cancer Res, 2018 Sep 06; 20(1). PMID: 30180877    Free PMC article.
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
André Filipe Vieira, Fernando Schmitt.
Front Med (Lausanne), 2018 Sep 21; 5. PMID: 30234119    Free PMC article.
Review.
Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study.
Wei Wang, Xiaosong Chen, +12 authors, Kunwei Shen.
J Cancer, 2018 Oct 03; 9(18). PMID: 30271480    Free PMC article.
Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis.
Shuning Ding, Jiayi Wu, +6 authors, Li Zhu.
Oncologist, 2019 Apr 26; 24(11). PMID: 31019021    Free PMC article.
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Maria Vittoria Dieci, Valentina Guarneri, +16 authors, Veneto Oncology Network.
Oncologist, 2019 Jun 04; 24(11). PMID: 31152079    Free PMC article.
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
Review.
Olfactory receptor gene abundance in invasive breast carcinoma.
Shirin Masjedi, Laurence J Zwiebel, Todd D Giorgio.
Sci Rep, 2019 Sep 26; 9(1). PMID: 31551495    Free PMC article.
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Tanja Ovcaricek, Iztok Takac, Erika Matos.
Radiol Oncol, 2019 Sep 26; 53(3). PMID: 31553709    Free PMC article.
Review.
21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.
Wei Wang, Lin Lin, +11 authors, Kunwei Shen.
Oncol Lett, 2019 Oct 04; 18(4). PMID: 31579428    Free PMC article.
GSIAR: gene-subcategory interaction-based improved deep representation learning for breast cancer subcategorical analysis using gene expression, applicable for precision medicine.
Chiranjib Sur.
Med Biol Eng Comput, 2019 Oct 09; 57(11). PMID: 31591679
The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study.
Tim C de Ruijter, Kim M Smits, +7 authors, Vivianne C G Tjan-Heijnen.
Diagn Progn Res, 2019 Oct 24; 3. PMID: 31641693    Free PMC article.
Impact of the 21-gene recurrence score assay on chemotherapy decision making and outcomes for breast cancer patients with four or more positive lymph nodes.
Qing-Hong Zhang, Wen-Wen Zhang, +4 authors, San-Gang Wu.
Ann Transl Med, 2019 Nov 09; 7(18). PMID: 31700882    Free PMC article.
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Salomon M Stemmer, Mariana Steiner, +16 authors, David B Geffen.
NPJ Breast Cancer, 2019 Nov 16; 5. PMID: 31728408    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
DNA methylation markers predict recurrence-free interval in triple-negative breast cancer.
Mary Jo Fackler, Soonweng Cho, +12 authors, Christopher B Umbricht.
NPJ Breast Cancer, 2020 Feb 07; 6. PMID: 32025567    Free PMC article.
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Wendy A Woodward, William E Barlow, +15 authors, Kathy S Albain.
JAMA Oncol, 2020 Jan 10; 6(4). PMID: 31917424    Free PMC article.
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Philip D Poorvu, Shari I Gelber, +12 authors, Ann H Partridge.
J Clin Oncol, 2019 Dec 07; 38(7). PMID: 31809240    Free PMC article.
Indications for prognostic gene expression profiling in early breast cancer.
Erin F Cobain, Daniel F Hayes.
Curr Treat Options Oncol, 2015 May 02; 16(5). PMID: 25929335
Review.
Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.
Johan Vallon-Christersson, Jari Häkkinen, +12 authors, Johan Staaf.
Sci Rep, 2019 Aug 23; 9(1). PMID: 31434940    Free PMC article.
21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
Yiwei Tong, Jiayi Wu, +6 authors, Kunwei Shen.
Sci Rep, 2019 Sep 13; 9(1). PMID: 31511599    Free PMC article.
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Andreas Heindl, Ivana Sestak, +3 authors, Yinyin Yuan.
J Natl Cancer Inst, 2017 Sep 02; 110(2). PMID: 28859291    Free PMC article.
Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Andreana N Holowatyj, Michele L Cote, +5 authors, Kristen S Purrington.
J Clin Oncol, 2018 Jan 18; 36(7). PMID: 29341832    Free PMC article.
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Abiola F Ibraheem, David J Press, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2018 Nov 06; 125(2). PMID: 30387876    Free PMC article.
Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
Kevin Kalinsky, Ruth M O'Regan.
Cancer, 2018 Nov 06; 125(2). PMID: 30387877    Free PMC article.
Mitotic slippage: an old tale with a new twist.
Debottam Sinha, Pascal H G Duijf, Kum Kum Khanna.
Cell Cycle, 2019 Jan 03; 18(1). PMID: 30601084    Free PMC article.
Review.
PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA.
Liping Tan, Dongmei Mai, +17 authors, Dongxin Lin.
Mol Cancer, 2019 Jan 15; 18(1). PMID: 30636640    Free PMC article.
Highly Cited.
Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review.
Ang Zheng, Lin Zhang, +2 authors, Feng Jin.
Am J Mens Health, 2019 May 10; 13(3). PMID: 31068065    Free PMC article.
Review.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
A framework for the development of effective anti-metastatic agents.
Robin L Anderson, Theo Balasas, +16 authors, Cancer Research UK and Cancer Therapeutics CRC Australia Metastasis Working Group.
Nat Rev Clin Oncol, 2018 Dec 06; 16(3). PMID: 30514977    Free PMC article.
Highly Cited.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.
Review.
Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review.
David Krug, René Baumann, +12 authors, Rolf Sauer.
Breast Care (Basel), 2020 May 14; 15(2). PMID: 32398980    Free PMC article.
Review.
21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort.
J Bryan Iorgulescu, Rachel A Freedman, +2 authors, Jane E Brock.
JCO Precis Oncol, 2019 Jan 01; 3. PMID: 32457931    Free PMC article.
Use of MRI for Personalized Treatment of More Aggressive Tumors.
Riham H El Khouli, Michael A Jacobs.
Radiology, 2020 Apr 03; 295(3). PMID: 32233918    Free PMC article.
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer.
K Almstedt, S Mendoza, +9 authors, M Schmidt.
Breast Cancer Res Treat, 2020 May 22; 182(1). PMID: 32436145    Free PMC article.
Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.
Vincent P Walter, Florin-Andrei Taran, +6 authors, Andreas Daniel Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Jun 23; 80(6). PMID: 32565552    Free PMC article.
A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management.
Natalia R Kunst, Fernando Alarid-Escudero, A David Paltiel, Shi-Yi Wang.
Value Health, 2019 Sep 30; 22(10). PMID: 31563252    Free PMC article.
Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.
Fei Wang, Sonya Reid, +6 authors, Xiao-Ou Shu.
Clin Cancer Res, 2019 Nov 22; 26(1). PMID: 31748278    Free PMC article.
An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer.
Yi-Xing Wang, Yuan-Yuan Wang, +9 authors, Ju-Lun Yang.
Breast, 2020 Jan 09; 49. PMID: 31911370    Free PMC article.
Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.
Alberto Zambelli, Edda Simoncini, +11 authors, Carlo Tondini.
Breast, 2020 Apr 24; 52. PMID: 32325372    Free PMC article.
Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
Garazi Serna, Sara Simonetti, +10 authors, Paolo Nuciforo.
Breast, 2020 Jul 25; 53. PMID: 32707454    Free PMC article.
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry.
Barbara L Smith, Anvy Nguyen, +6 authors, Michele A Gadd.
Breast Cancer Res Treat, 2020 Jul 28; 183(3). PMID: 32712878    Free PMC article.
Review.
Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study.
Jiayi Wu, Shuning Ding, +16 authors, Li Zhu.
Cancer Res Treat, 2020 Feb 06; 52(3). PMID: 32019280    Free PMC article.
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Abiola Ibraheem, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2020 Jun 11; 126(17). PMID: 32521056    Free PMC article.
The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database.
In Sil Choi, Jiwoong Jung, +5 authors, Ki-Tae Hwang.
Cancers (Basel), 2020 Jul 12; 12(7). PMID: 32650374    Free PMC article.
Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test.
Susan K Boolbol, Manju Harshan, +8 authors, Stephen Malamud.
Breast Cancer Res Treat, 2019 Jul 16; 177(3). PMID: 31302854    Free PMC article.
Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer.
San-Gang Wu, Wen-Wen Zhang, +3 authors, Zhen-Yu He.
Onco Targets Ther, 2019 Apr 10; 12. PMID: 30962690    Free PMC article.
21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer.
Wen-Wen Zhang, Qin Tong, +8 authors, Huan-Xin Lin.
Front Oncol, 2019 May 02; 9. PMID: 31041190    Free PMC article.
Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study.
Vahit Özmen, Burcu Çakar, +7 authors, Pınar Saip.
Eur J Breast Health, 2019 Jul 18; 15(3). PMID: 31312795    Free PMC article.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Review.
Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test.
Debbie M Jakubowski, Helen Bailey, +7 authors, Frederick L Baehner.
J Surg Oncol, 2020 Jun 05;. PMID: 32497318    Free PMC article.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
Review.
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Thomas M Schwedhelm, Judy R Rees, +4 authors, Erika L Moen.
BMC Cancer, 2020 Sep 05; 20(1). PMID: 32883270    Free PMC article.
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Yunan Han, Zhi-Feng Miao, +3 authors, Ying Liu.
Breast Cancer Res Treat, 2020 Sep 16; 184(3). PMID: 32929567    Free PMC article.
Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study.
Katsuhiro Yoshikawa, Mitsuaki Ishida, +3 authors, Tomoharu Sugie.
PLoS One, 2020 Nov 18; 15(11). PMID: 33201923    Free PMC article.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Ulrike Nitz, Oleg Gluz, +18 authors, Nadia Harbeck.
Breast Cancer Res Treat, 2017 Jul 01; 165(3). PMID: 28664507    Free PMC article.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Hiroji Iwata, Norikazu Masuda, +19 authors, Yasuo Ohashi.
Breast Cancer Res Treat, 2018 Sep 23; 173(1). PMID: 30242578    Free PMC article.
SEOM clinical guidelines in early stage breast cancer (2018).
F Ayala de la Peña, R Andrés, +7 authors, E Ciruelos.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30443868    Free PMC article.
Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers: Preliminary results for correlation with Oncotype DX recurrence scores.
Kyung Jin Nam, Hyunjin Park, +3 authors, Jeong Eon Lee.
Medicine (Baltimore), 2019 Jun 07; 98(23). PMID: 31169691    Free PMC article.
Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Mariana Bustamante Eduardo, Vlad Popovici, +5 authors, Rolf Jaggi.
BMC Cancer, 2019 Jun 09; 19(1). PMID: 31174485    Free PMC article.
Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer.
Abdulmohsen Alkushi, Ahmad Omair, +2 authors, Omalkhair Abualkhair.
Breast Cancer (Auckl), 2020 Dec 22; 14. PMID: 33343196    Free PMC article.
Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.
Ping Zhou, Wen-Wen Zhang, +4 authors, San-Gang Wu.
Breast, 2020 Dec 06; 54. PMID: 33278648    Free PMC article.
Insights into the theranostic value of precision medicine on advanced radiotherapy to breast cancer.
Man Jiang, Jianshe Yang, +3 authors, Meiqin Tang.
Int J Med Sci, 2021 Jan 14; 18(3). PMID: 33437197    Free PMC article.
Review.
The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes.
Lucie Laot, Enora Laas, +12 authors, Anne-Sophie Hamy.
Cancers (Basel), 2021 Jan 10; 13(2). PMID: 33418983    Free PMC article.
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Katya Losk, Rachel A Freedman, +7 authors, Tari A King.
Breast Cancer Res Treat, 2020 Sep 18; 185(1). PMID: 32939592
Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Kent F Hoskins, Oana C Danciu, Naomi Y Ko, Gregory S Calip.
JAMA Oncol, 2021 Jan 22; 7(3). PMID: 33475714    Free PMC article.
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®.
Richard Buus, Zsolt Szijgyarto, +10 authors, Maggie Chon U Cheang.
NPJ Breast Cancer, 2021 Feb 14; 7(1). PMID: 33579961    Free PMC article.
The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
Roi Weiser, Waqar Haque, +4 authors, V Suzanne Klimberg.
Breast Cancer Res Treat, 2020 Oct 19; 185(3). PMID: 33070279
Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Maroun Bou Zerdan, Maryam Ibrahim, +2 authors, Hazem I Assi.
Front Oncol, 2021 Mar 06; 10. PMID: 33665165    Free PMC article.
Review.
How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients.
Xiaofu Zhu, Susan Dent, +5 authors, Xinni Song.
Curr Oncol, 2021 Feb 10; 28(1). PMID: 33557029    Free PMC article.
Prognostic Cancer Gene Expression Signatures: Current Status and Challenges.
Yuquan Qian, Jimmy Daza, +4 authors, Andreas Teufel.
Cells, 2021 Apr 04; 10(3). PMID: 33804045    Free PMC article.
Review.
Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer.
Minji Koh, Jinhong Jung, +6 authors, Jae Ho Jeong.
Breast Cancer Res Treat, 2021 Apr 24;. PMID: 33891300